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1. Introduction
Historically chemotherapy for the treatment of colorectal cancer consisted of the thymidy‐
late synthase inhibitor 5-FU (Adrucil®, Fluouracil®, Efudex®, Fluoroplex®), or more recently
it’s oral pro-drug Capecitabine (Xeloda®), in combination with Folinic acid. Alone these
agents were associated with overall tumour response rates in the order of 20%.[10] In the
last decade newer agents such as Oxaliplatin and Irinotecan have emerged on the market.
These agents are not administered alone but normally in combination with a thymidylate
synthase inhibitor. These combinations have seen the reported objective response to chemo‐
therapy rise to typical rates of 50%.[11-13]
In parallel with the development of these conventional chemotherapeutics a new class of bi‐
ological agents, i.e. antibody based therapies, have emerged. These agents are used to tackle
specific pathways in tumour growth and development such as angiogenesis (e.g. anti-VEG‐
FA antibody Bevacizumab) or cellular proliferation (e.g. the anti-epidermal growth factor
antibodies Cetuximab and Panitumumab). When these agents are added to Oxaliplatin or
Irinotecan based chemotherapy a further 10-15% increase in overall tumour response rate
can be obtained.[14-17]
This improvement in response rates has led to a resurgence of interest in utilising chemo‐
therapy as a means of down-sizing metastatic disease to enable subsequent surgical resec‐
tion – so called conversion chemotherapy.[18] This approach was initially described in 1996
in a series of 330 patients with inoperable colorectal liver metastases of whom 53 (16%) were
able to undergo a subsequent liver resection with curative intent after receiving systemic
chemotherapy. The five year survival for these patients was 40% which compared favoura‐
bly to patients with operable disease treated with surgery alone during the same period.[19]
In 2004 the same group reported the outcome of 1104 patients with initially unresectable col‐
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orectal liver metastases who were treated primarily with systemic chemotherapy over an 11
year period from 1988 – 1999. Of this cohort 138 patients had a sufficient response to chemo‐
therapy to permit subsequent curative intent surgery with an overall 5 year survival of 33%
being achieved.[20]
In a small phase II trial of 42 patients with inoperable colorectal liver metastases Alberts et al
reported that systemic treatment with 5-FU/Oxaliplatin was associated with a tumour re‐
sponse rate of around 60% with 14 patients (33%) having a sufficient response to permit a
liver resection with curative intent.[21] Similar results have been reported with a 5-FU/Irino‐
tecan regimen by Nuzzo et al with 15 out of 42 patients (36%) with inoperable disease being
able to undergo subsequent surgical treatment.[22] In an attempt to determine the most ap‐
propriate regimen for use as conversion chemotherapy the GERCOR trial randomised pa‐
tients with inoperable metastatic colorectal cancer to receive either 5-FU/Irinotecan until
disease progression or unacceptable toxicity and then 5-FU/Oxaliplatin or the reverse se‐
quence (n=113 per arm). Those patients receiving first line Oxaliplatin demonstrated a high‐
er resection rate (n=24; 22%) than those receiving first line Irinotecan (n=10; 9%) and as such
this is the approach most commonly applied in UK practice.[23]
More recently studies have been designed to determine the role of the biological agents in
conversion therapy. In the phase II uncontrolled BOXER trial 46 patients with inoperable
colorectal liver metastases were treated with Capecitabine/Oxaliplatin in combination with
Bevacizumab. 35 of these patients experienced an objective tumour response with 18 (40%)
able to undergo a liver resection with curative intent. In addition 5 patients (11%) experi‐
enced a complete radiological response to systemic therapy.[24] The CRYSTAL trial rando‐
mised patients with inoperable metastatic disease to Irinotecan/5-FU either alone or in
combination with Cetuximab and found that the addition of Cetuxmiab was more likely to
result in patients undergoing subsequent R0 liver resection with curative intent (Odds Ratio
3.02; p=0.002).[17] It is important to note that the response to Cetuximab is primarily deter‐
mined by KRAS mutation status. In the Crystal trial there was no evidence of benefit in pa‐
tients with mutant KRAS who received Cetuximab as compared to those who received 5-
FU/Irinotecan alone.[25]
For those patients who receive successful conversion chemotherapy and are subsequently
considered for liver resection with curative intent it is important to be aware of what the
likely long term outcome will be. Adam et al. reported a series of 184 patients with initially
inoperable disease who underwent hepatectomy after systemic therapy. In these patients a 5
year overall survival rate of 33% was obtained although it is important to note that a signifi‐
cant proportion of patients in this study underwent 2 or more surgical procedures, often in‐
terspersed with further chemotherapy, before long lasting disease control was obtained.[26]
Whilst the role of conversion chemotherapy is widely accepted in the HPB community more
recently the question has been asked about what role systemic therapy may play in the man‐
agement of patients presenting with operable disease from the outset i.e. true neoadjuvant
chemotherapy. The EPOC trial was a multicentre randomised controlled trial which allocat‐
ed such patients to receive either surgery alone or 6 cycles of 5-FU/Oxaliplatin prior to sur‐
gery followed by a further 6 cycles of therapy after surgery (n=182 per arm). Of those
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patients randomised just over 80% of patients in both arms underwent a curative intent liver
resection. When the results of this study were analysed on an intention to treat basis there
was a non-significant trend to improved 3 year overall survival in the chemotherapy arm
(35.4% vs. 28.1%; p=0.058) although statistical significance was only achieved when the anal‐
ysis was limited to only those who underwent resection (42.4% vs. 33.2%; p=0.025).[27] The
difficulty in interpretation of the EPOC trial is that it is impossible to know whether the ben‐
efits of peri-operative chemotherapy were primarily a result of the neoadjuvant or adjuvant
treatment or if both are required. This important question remains, at present, unanswered.
At present most authors would agree that there is insufficient evidence to consider all pa‐
tients with operable disease candidates for systemic therapy prior to surgery although it
may play a role in those with poor prognostic features such as multiple tumour deposits, a
large tumour size or extra-hepatic disease.[28, 29] What is clear however is that an ever in‐
creasing number of patients are presenting for surgical resection on the background of mul‐
tiple cycles of chemotherapy.[30] As experience of managing this patient cohort has
increased there has been a growing recognition that the use of chemotherapy can be associ‐
ated with a toxic injury to the liver parenchyma.[31] The nature of this liver injury and its
implication for the surgical approach to these patients will form the subject of the remainder
of this chapter.
2. Chemotherapy associated liver injury
2.1. Steatosis/steatohepatitis
The presence of fatty change within the liver is increasingly prevalent in the general adult
population where it is commonly associated with the presence of obesity and insulin resist‐
ance (i.e. the metabolic syndrome). Fatty liver disease represents a spectrum of changes
within the liver ranging from simple steatosis through to steatohepatitis and in extreme cas‐
es cirrhosis.[32] Steatohepatitis differs from simple steatosis in that significant inflammatory
infiltrates are present in the liver commonly in association with ballooning degeneration of
hepatocytes.[33]
The link between chemotherapy use and fatty liver disease was first reported in the litera‐
ture in 1998. In a series of 21 patients with colorectal liver metastases treated with systemic
5-FU Peppercorn et al. reported that 48% (n=10) of patients had developed radiological evi‐
dence of steatosis on follow-up imaging.[34] In a later series Pawlik et al. reported the histo‐
logical findings in the liver parenchyma of 334 patients who had undergone resection of
colorectal liver metastases, 153 of whom had received pre-operative chemotherapy. In this
study steatosis ≥ 30% (i.e. steatosis affecting more than 30% of hepatocytes) was present in
18.4% of patients who received pre-operative chemotherapy as compared to only 3.4% of pa‐
tients who were chemotherapy naive (p=0.004). In particular the authors observed that stea‐
tosis was most strongly associated with Irinotecan based chemotherapy (27.3% of patients;
p<0.001) than 5-FU monotherapy (14.9%; p=0.03) and lastly Oxaliplatin based chemotherapy
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(9.6%; p=0.04) suggesting that the nature of the chemotherapy regimen may be important in
determining liver toxicity.[35]
In contrast however a separate series of 406 patients who underwent resection of colorec‐
tal  liver  metastases  failed to  demonstrate  any association between the administration of
pre-operative chemotherapy and the subsequent development of steatosis ≥ 30%. In those
receiving Irinotecan based chemotherapy (n=94)  there  was  however  a  dramatic  increase
in the incidence of steatohepatitis as compared to those patients who were chemotherapy
naive (20.2% vs. 4.4%; p=0.001), a finding which was in contrast to the smaller study de‐
scribed above.[35, 36]
To more accurately determine the nature of the association between chemotherapy use and
the development of fatty change within the liver our group undertook a systematic review
and meta-analysis of the published literature. In this analysis it was not possible to demon‐
strate any association with chemotherapy use overall (Relative Risk 1.25; 95% confidence in‐
terval 0.99 – 1.57; p=0.15) or Oxaliplatin based chemotherapy (Relative Risk 0.98; 95%
confidence interval 0.59 – 1.63; p=0.95) and the development of steatosis ≥ 30%. In the case of
Irinotecan based chemotherapy there was a strong trend to an increased risk of steatosis >
30% (Relative Risk 2.51; 95% Confidence Interval 0.79 – 7.90; p=0.12) which was not statisti‐
cally significant as a consequence of the heterogeneity within the included studies. In con‐
trast there was a strong association between Irinotecan based chemotherapy and
steatohepatitis (Relative Risk 3.45; 95% Confidence Interval 1.12 – 10.62; p=0.03) which was
not demonstrated with other regimens.[37]
2.2. Sinusoidal obstruction syndrome
Sinusoidal obstruction syndrome (SOS; previously known as hepatic veno-occlusive dis‐
ease) represents a microvascular injury to the liver characterised by the histological findings
of dilatation of the hepatic sinusoids and associated atrophy of the surrounding hepatocytes.
In more advanced SOS these changes are accompanied by the development of regenerative
nodules within the liver and ultimately peri-sinusoidal liver fibrosis.[38] Historically SOS
was described as a condition occurring after ingestion of pyrrolizidine alkaloids, a group of
compounds found in plants used in traditional African herbal remedies.[39, 40] Furthermore
SOS has been reported to occur in up to 50% of patients receiving myeloablative chemother‐
apy prior to bone marrow transplantation.[41, 42]
In a seminal paper in 2004 Rubbia-Brandt published a report of histological changes in the
liver parenchyma of 153 patients who had undergone resection of colorectal liver metasta‐
ses. In this study it was reported that 44 out of 87 patients treated with pre-operative chemo‐
therapy had histological features of SOS, the majority of whom had received treatment with
Oxaliplatin based regimens.[38] Similar results were reported by Vauthey et al who demon‐
strated a significantly increased incidence of SOS in patients receiving Oxaliplatin based
chemotherapy as compared to those who were chemotherapy naive (18.9% vs. 1.9%;
p<0.001) where as no such association was demonstrated with other chemotherapy regi‐
mens.[36] In our systematic review of the published literature we demonstrated a strong as‐
sociation between Oxaliplatin based chemotherapy and SOS (Relative Risk 2.78; 95%
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Confidence Interval 1.35 – 5.69; p=0.0007) which again was not replicated in patients receiv‐
ing alternative chemotherapy regimens.[37] The typical appearances of an Oxaliplatin in‐
jured liver, as encountered at laparotomy, are shown in Figure 1.
Figure 1. The classical appearance of the Oxaliplatin injured liver with SOS – commonly described as a “blue liver”
It is therefore clear from this discussion that the nature of liver injury following administra‐
tion of chemotherapy to patients with colorectal liver metastases is dependent on the nature
of the regimen administered. Irinotecan based regimens are primarily associated with the
development of hepatic steatosis/steatohepatitis whereas Oxaliplatin based regimens are as‐
sociated with the development of SOS. The assessment of the severity of this liver injury and
its implications for the surgical management of these patients forms the discussion in the re‐
mainder of this chapter.
3. Assessment of the post-chemotherapy liver
Post hepatectomy liver failure (PHLF) is a feared complication of major liver resection and
was recently defined as “a postoperatively acquired deterioration in the ability of the liver to
maintain its synthetic, excretory and detoxifying functions”[43] whose presence is associat‐
ed with a dramatic increase in the risk of post-operative mortality.[44, 45]
A key risk factor for the development of PHLF is the presence of background liver disease or
injury. Belghiti et al reported, in a series of 747 patients undergoing liver resection, that the
presence of either cirrhosis or steatosis affecting more than 30% of hepatocytes (n=253) was
associated with a post-operative mortality of 9.5% as compared to only 1% in those with a
normal liver parenchyma.[46] In a series of 406 patients undergoing resection of colorectal
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liver metastases Vauthey et al reported that those patients with steatohepatitis (n=34) experi‐
enced an increase in both 90 day mortality (14.7% vs. 1.6% p = 0.001) and post hepatectomy
liver failure (5.8% vs. 0.8%; p=0.01).[36] The findings from these case series have been sup‐
ported by a meta-analysis of the published literature which demonstrated that the presence
of hepatic steatosis > 30% was associated with an increased risk of peri-operative complica‐
tions (risk ratio 2.01; p<0.0001) and mortality (risk ratio 2.79; p=0.02).[47] Similarly the pres‐
ence of SOS has been associated with an increased incidence of PHLF in a series of 51
patients undergoing resection of CRLM, 38 of whom had histologically proven SOS (68% vs.
23%; p=0.004)[48]
The other factor that is pivotal in determining the risk of PHLF is the volume of liver which
will remain following surgery, commonly referred to as the future liver remnant or FLR,
which can often be estimated pre-operatively by CT volumetry.[49] In 2003 Shoup et al re‐
ported a series of 126 patients who had undergone a liver resection to treat colorectal liver
metastases. In those patients with a FLR of ≤ 25% (n=20) 90% developed PHLF as compared
to 19% of those with an FLR > 25%. Logistic regression analysis demonstrated that the pres‐
ence of an FLR<25% tripled the risk of PHLF (Odds Ratio 3.09; p<0.0001). Similarly in a
study of 119 patients with a normal liver parenchyma undergoing major liver resection (i.e.
resection of 3 or more Couinaud segments) the median FLR in the 7 patients who developed
PHLF was 29.6% as compared to 42.5% in those who did not (p=0.009).[50] As a conse‐
quence of this evidence the minimum safe FLR in patients with an otherwise normal liver
undergoing resection of CRLM is 25%.[51]
In those patients presenting for surgery on the background of multiple cycles of pre-opera‐
tive chemotherapy it is pivotal, particularly when an extensive liver resection is planned, to
minimise the risk of PHLF. When significant parenchymal injury is present it may be neces‐
sary for the FLR to be as high as 40% and this may have a significant impact on the surgical
strategy employed.[52] Careful pre-operative assessment of the liver is therefore essential in
these patients and the techniques which can be employed for doing this are discussed in
more detail below.
3.1. Clinical/biochemical markers of chemotherapy induced liver injury
Identifying those patients at risk of steatohepatitis following Irinotecan based chemotherapy
is particularly difficult not least because a significant proportion of patients in the back‐
ground community will have a fatty liver as a consequence of either the metabolic syn‐
drome, other underlying liver disease or lifestyle. This is reflected in the study of Ryan et al.
which analysed histological changes in the liver of 334 patients undergoing resection of col‐
orectal metastases. Only 8 patients in this study had histologically defined steatohepatitis
the presence of which, on multivariate analysis, was found to be independently associated
with a BMI > 30kg/m2 but not the use of chemotherapy.[53] The study of Vauthey et al. re‐
ported that, in 94 patients treated with Irinotecan, the incidence of steatohepatitis was 12.1%
in those with a BMI of < 25kg/m2 but 24.6% in those with a BMI of ≥ 25kg/m2. This study did
not however undertake a multivariate analysis to identify independent risk factors associat‐
ed with the presence of steatohepatitis.[36] It has been proposed that elevated serum transa‐
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minases may be of use in determining simple steatosis from steatohepatitis in patients with
non-alcoholic fatty liver disease but it is not know whether this observation also holds true
in those with chemotherapy associated steatohepatitis.[54-56]
Whilst one might intuitively expect that there would be a direct correlation between the
number of cycles of chemotherapy received and the presence of liver injury this relationship
is in fact less than clear cut. In the study of Vauthey et al. which reported the presence of
liver injury in 406 patients undergoing resection of colorectal metastases there was no asso‐
ciation between the number of cycles of chemotherapy administered and the incidence of
steatohepatitis or SOS.[36] On the other hand Kishi et al., in a series of 219 patients who
were treated pre-operatively with Oxaliplatin based chemotherapy, reported that SOS was
present more frequently in those who received 9 or more cycles of chemotherapy than those
who did not (42% vs. 26%; p=0.017).[57] Similarly the study of Aloia et al. reported that the
incidence of SOS in those receiving greater than 12 cycles of chemotherapy was 50% as com‐
pared to 25% in those receiving 6-12 cycles and 10% in those who received less than 6 cycles
(p=0.01).[58] Several studies have undertaken multivariate analysis to identify independent
risk factors associated with the development of chemotherapy induced liver injury. Nakano
et al demonstrated that the presence of SOS was independently associated with receiving 6
or more cycles of Oxaliplatin based chemotherapy (Relative Risk 3.2; p=0.048).[59] In con‐
trast however 3 other studies have failed to demonstrate any such independent association
between the number of cycles of Oxaliplatin administered and the development of SOS.[48,
60, 61] This raises the question of whether other variables, such as the presence of underly‐
ing liver disease, also make a significant contribution to the development of chemotherapy
induced liver injury.
Some authors have suggested that tumour related factors may play a role in determining the
development of SOS. On a univariate analysis of 78 patients treated with pre-operative Oxa‐
liplatin based chemotherapy Soubrane et al. reported that those with SOS tended to have a
larger tumour size (7.8cm vs. 5.2cm; p = 0.004) although this was not identified as an inde‐
pendent risk factor on multivariate analysis.[48] Tamandl et al. were able to confirm this ob‐
servation in a separate study and on this occasion they were able to demonstrate that a
tumour size > 5cm was independently associated with the development of SOS on multi‐
variate analysis (Hazard Ratio 4.42; p = 0.012).[61] This clinical data is supported by experi‐
mental data from our group which suggests that the presence of tumour within the liver of
mice treated with Oxaliplatin based chemotherapy accelerates changes in gene expression
associated with the development of SOS.[62]
The role of various haematological and biochemical parameters to predict the presence of
SOS has also been explored in several studies. Soubrane et al. reported on univariate analy‐
sis that an elevated AST (p=0.0009), ALT (p=0.02) and a low platelet count (p<0.0001) were
all suggestive of the presence of SOS. On multivariate analysis they demonstrated that a
high AST to platelet count ratio (APRI score) was an independent predictor for the presence
of SOS (Odds Ratio 5; p<0.005).[48] Similarly a multivariate analysis from Nakano et al.
demonstrated an independent association between an elevated AST and the presence of SOS
(Relative Risk 3.86; p=0.044). [59] Tamandl et al. reported that on multivariate analysis on
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multivariate analysis an elevated alkaline phosphatase or γGT was an independent predic‐
tor of SOS (Hazard Ratio 4; p=0.038) although this was not true for AST or ALT.[61]
Whilst none of these studies have demonstrated a single factor that is reliably able to predict
the presence of chemotherapy induced liver injury it is possible to begin to develop a picture
of the patient characteristics which may lead to a raised index of suspicion and prompt a
more thorough assessment of the liver parenchyma prior to surgery.
3.2. Radiological assessment of chemotherapy induced liver injury
The volume of data on the radiological assessment of fatty liver disease is vast and this is a
reflection of the high incidence of non-alcoholic fatty liver disease in the general population.
The consequence of this is that the appearances of fatty liver disease on each of the 3 main
imaging modalities of the liver have been well described and is summarised in Table 1. It
should be pointed out that on CT scanning hepatic steatosis is best detected on unenhanced
images which are often not performed routinely in most imaging protocols in order to mini‐
mise patient radiation exposure.[63] A recent systematic review and meta-analysis of the
published literature concluded that MRI represented the most accurate method for deter‐
mining the extent of hepatic steatosis with a reported sensitivity of 97.4% and specificity of
76.1% for the detection of steatosis >30%.[64]
Imaging Modality Characteristic features hepatic steatosis
Ultrasound Intracellular fat accumulation leads to an increase in liver echogenicity [63]
Computed Tomography Steatosis leads to a decrease in attenuation of the liver parenchyma [63, 65]
Magnetic Resonance Imaging A loss of liver signal intensity occurs on T1 weighted gradient echo (GRE) opposed
images[63, 65]
Table 1. Appearances of hepatic steatosis on the main liver imaging modalities
Several studies have attempted to identify the utility of pre-operative cross sectional imag‐
ing to identify hepatic steatosis specifically in patients undergoing liver resection. The first
of these was published in 2008 by Cho et al. who conducted a retrospective analysis of 131
patients undergoing partial hepatectomy over a 4 year period who had one of either a non-
contrast CT scan (n=26), contrast enhanced CT scan (n=74) or a gradient opposed MRI (n=32)
with a median interval between imaging and surgery of 17 Days. The ability of these imag‐
ing modalities to predict histologically defined steatosis > 30% was determined. The authors
demonstrated that of the two CT methods studied only non-contrast CT was of any utility in
determining the presence of hepatic steatosis with a high degree of specificity (100%) but
had low sensitivity (33%) with a corresponding positive predictive value (PPV) of 100% and
negative predictive value (NPV) of 83%. In contrast MRI fared much better in excluding the
presence of hepatic steatosis with an NPV of 94% but a PPV of only 44% with a sensitivity of
88% and specificity of 63%. The conclusion of this study was that cross-sectional imaging
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alone was not consistently able to determine the presence of hepatic steatosis and was there‐
fore of limited utility for this purpose.[66]
In 2009 O’Rourke et al. reported a prospective study of n=37 patients undergoing resection
of colorectal liver metastases who received pre-operative liver specific MRI. Again this
study demonstrated a much better performance for MRI in determining the presence of hep‐
atic steatosis > 30% with a PPV of 100%, NPV of 87% a sensitivity of 63% and a specificity of
100%.[67] A subsequent retrospective study by Marsman et al compared the ability of non-
contrast enhanced CT (n=32) and MRI (n=36) to detect the presence of histologically defined
steatosis > 33% in patients undergoing resection of colorectal liver metastases after receiving
pre-operative chemotherapy. In this study MRI by far out performed CT in terms of sensi‐
tivity (78% vs. 70%), specificity (100% vs. 86.4%); PPV (100% vs. 70%) and NPV (93.1% vs.
86.4%) suggesting that this is the imaging modality of choice.[68]
On the basis of the currently available evidence it appears that MRI is the imaging modality
of choice to assess the extent of hepatic steatosis in patients with colorectal liver metastases
prior to surgery. It must be highlighted that cross-sectional imaging is not able to differenti‐
ate between simple steatosis and steatohepatitis which can only be achieved with histologi‐
cal assessment of the liver. Furthermore a ‘normal’ imaging study does not exclude the
presence of hepatic steatosis and in those cases where there is a high level of clinical suspi‐
cion a further evaluation of the liver must be undertaken.
The role of cross-sectional imaging in detecting the presence of SOS is much less clear cut as
compared to hepatic steatosis. It has been proposed that the development of splenomegaly
on post-chemotherapy imaging may serve as a surrogate marker for the presence of SOS.
Overman et al conducted a study in patients who received either 5-FU/Oxaliplatin (n=96) or
5-FU alone (n=40) as adjuvant therapy following resection of a colonic primary and com‐
pared spleen size on pre-operative imaging to that 6 weeks after the final cycle of chemo‐
therapy. They demonstrated that the median increase in spleen size was 22% for those
patients receiving 5-FU/Oxaliplatin whereas there was no increase in size in those receiving
5-FU alone (p<0.001). The authors went on to look at a subgroup of patients (n=63) who un‐
derwent a liver resection after 5-FU/Oxaliplatin and demonstrated, on multivariate analysis,
that a greater than 50% increase in spleen size following chemotherapy was independently
able to predict the presence of SOS (Odds Ratio 2.34; p=0.02) with a sensitivity of 43%, and
specificity of 90%.[60]
Several authors have explored the utility of various MRI protocols to predict the presence of
SOS. Ward et al. reported a study of 60 patients with colorectal liver metastases who under‐
went superparamagnetic iron oxide (SPIO) enhanced MRI prior to liver resection. Following
SPIO administration SOS is characterised by reticular hyperintensity on T2*-gradient re‐
sponse echo weighted MRI images the presence of which the authors graded on a scale of 0
– 3 (summarised in Table 2) with a score of 2 or greater indicating the presence of SOS. Us‐
ing this technique 24 of the 60 patients were thought to have SOS on the basis of MRI the
presence of which was subsequently confirmed histologically in 20 patients. Of the 36 pa‐
tients thought not to have SOS on the basis of MRI 3 were subsequently found to have histo‐
logical features of SOS. This means that SPIO enhanced MRI, in this study, had a sensitivity
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of 87%, specificity of 89%, PPV of 83% and NPV of 92% for the presence of SOS.[69] In con‐
trast to these findings however O’Rourke et al. in their study of 37 patients found that SPIO
enhanced MRI had a high specificity (100%) and PPV (100%) for the presence of severe SOS
but a low sensitivity (11%) with a NPV of 78% suggesting that this technique may fail to
identify a significant proportion of patients with SOS.[67]
Grade Description
0 Absent
1 Fine reticulations on a minority of sections
2 Diffuse reticulations or localised coalescent areas of high signal
3 Diffuse reticulations present on all sections or densely coalescent areas of high signal on multiple
sections
Table 2. Grading of reticular hyperintensity on SPIO enhanced MRI to determine the presence of SOS[69]
Shin et al. explored the ability of Gadoxetic acid disodium (EOB-MRI; Primavist®) enhanced
MRI to detect the presence of SOS prior to resection of colorectal metastases. On EOB-MRI
the presence of SOS appears as reticular hypointensity which the authors graded on a scale
of 1-5 with a score of 4 (probably present) or 5 (definitely present) being considered diagnos‐
tic of SOS. Of the 42 patients included in this study all 12 MRI identified cases of SOS had
the diagnosis confirmed histologically and of the 30 MRI negative cases 4 had histological
evidence of SOS. This resulted in a sensitivity of 75%, specificity of 100%, PPV of 100% and a
NPV of 87%. The images in this study were independently reviewed by a radiological resi‐
dent with a good level of agreement (weighted kappa 0.765) suggesting that this technique
is subject to minimal interobserver variability.[70]
The small number of patients in these studies make it difficult to recommend the routine use
of any of these MRI protocols for the sole purpose of detecting pre-operative SOS. The pres‐
ence of splenomegaly on pre-operative imaging, particularly in patients who have received
multiple cycles of Oxaliplatin based chemotherapy, should raise suspicion about the pres‐
ence of SOS and prompt a thorough assessment of the liver parenchyma if extended resec‐
tion is to be performed.
3.3. Functional assessment of the future liver remnant
A variety of techniques have been described which aim to quantitatively assess the function‐
al reserve of the liver and thereby provide a means to determine the minimum safe FLR that
is required to avoid the risk of PHLF. Perhaps the most widely described of these techniques
is the Indocyanine Green (ICG) retention test. Following injection ICG is transported in the
systemic circulation bound to albumin and does not leave the serum until it reaches the liver
where it is taken up by hepatocytes. These hepatocytes then clear ICG by excreting the com‐
pound into the biliary system in an ATP dependent manner. ICG does not enter the portal
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circulation nor is it metabolised by hepatocytes prior to its excretion and therefore the clear‐
ance of ICG provides a direct measure of hepatocyte function.[71]
Typically the retention of ICG at 15 minutes is measured in a serum sample (ICGR-15) and
this value is used as a measure of hepatic functional reserve with a value of <10% being con‐
sidered normal. Based on their experience of using this test in a series of 1429 patients Ima‐
mura et al. described the maximum extent of liver resection they thought could be safely
performed according to the ICGR-15 value (see Table 3).[72] Others however view this
ICGR-15 value as too conservative and state that a cut off of <14% should be used to identify
those patients in whom it is safe to perform major liver resection.[73] The use of ICG reten‐
tion as a pre-operative assessment of liver function is however predominantly limited to
Asia where the majority of liver resections are performed for hepatocellular carcinoma and
therefore the data regarding the validity of this test in patients with colorectal liver metasta‐
ses is limited.
ICGR-15 Value Typical Safe Liver Resection
<10% Right/Left Trisectionectomy
10 – 19% Left hepatectomy / Right sectorectomy
20 – 29% Segmentectomy
≥ 30% Limited non-anatomical resection
Table 3. Typical safe liver resection volumes as recommended by Imamura et al based on ICGR-15 values[72]
Nakano et al reported the outcome of 36 patients who underwent major hepatectomy (>3
Couinaud segments) 20 of whom had histologically proven SOS and 16 who had a normal
liver parenchyma. The presence of SOS in these patients was independently associated with
an ICGR-15 of >10%. It is of note that these patients experienced an increased risk of peri-
operative complications (40% vs. 6.3%; p=0.026) and a longer mean hospital stay (17 days vs.
11 days; p = 0.006).[59] Experimental studies have also suggested that ICGR-15 may be a
useful measure of hepatocyte function in the context of hepatic steatosis.[74] In a series of
101 patients undergoing liver resection for colorectal metastases Klinger et al reported that
the use of preoperative chemotherapy (n=83; all regimens) was associated with a longer
ICGR-15 (7.3% vs. 3.5%; p = 0.005). Similarly those who had received pre-operative chemo‐
therapy were more likely to have an ICGR-15 ≥ 10% (27.7% vs. 0%; p=0.011) and this was
associated with an increased rate of post-operative complications (39.1% vs. 12.8%; p=0.005).
No attempt was made in this study to correlate ICGR-15 values with histological changes
within the liver parenchyma.[75]
The LiMAx test has recently been described as an alternative means of assessing the hepatic
functional reserve. This test measures the cytochrome P450 mediated metabolism of 13C la‐
belled methacetin into acetaminophen and 13CO2 which is exhaled. The test measures
changes in the ratio of exhaled 13CO2 : 12CO2 over a 60 minute period – the greater the 13CO2
excretion the greater the functional reserve of the liver.[76] The authors have demonstrated
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that low post-operative LiMAx values (<80µg/kg/h) are correlated with an unacceptable risk
of post-operative morbidity. On the basis of this they have proposed an algorithm to deter‐
mine the safety of liver surgery based upon pre-operative measurement of the LiMAx to cal‐
culate the likely post-operative LiMAx using CT volumetric calculations of the FLR. This
strategy has not however been proven in an independent prospective cohort and therefore
cannot currently be recommended for routine clinical use.[77]
A final technique for assessing the functional reserve of the liver is hepatobiliary scintigra‐
phy using 99mTc-mebrofenin. Following injection 99mTc-mebrofenin is taken up by hepato‐
cytes and excreted directly into the biliary system without prior intracellular metabolism in
a similar manner to ICG. The hepatic uptake and excretion of 99mTc-mebrofenin is deter‐
mined using images obtained with a gamma camera and from this it is possible to determine
the total liver uptake, corrected for body surface area, as a %/min/m2 of the total injected
dose (referred to as the total liver function or TL-F). In addition the FLR uptake function
(FLR-F) can be calculated as a function of the TL-F based on uptake in the calculated.[78]
De Graaf et al. reported a series 55 patients judged to be at high risk of post-operative com‐
plications following liver resection assessed with 99mTc-mebrofenin scintigraphy prior to liv‐
er resection. They demonstrated that TL-F was significantly reduced in those patients with
background parenchymal disease (7.4 vs. 8.5 %/min/m2; p=0.007). In addition the FLR-F was
significantly lower in those patients who developed PHLF as compared to those who did
not (2.2 vs. 4.3%/min/m2; p=0.001).[79] Whilst this technology needs further evaluation in
prospective studies it is likely that the emerging ability to perform single photon emission
computed tomography (SPECT) thereby enabling quantification of tracer compound activity
in combination with standard CT will lead to renewed interest in the technique.
At present none of these technologies have been adequately characterised in patients with
colorectal metastases undergoing liver resection. Whilst they undoubtedly have potential
merit in identifying those patients with an impaired hepatocyte mass it is not known wheth‐
er the information they add is superior to that obtained standard clinical and radiological
assessment. This must be established before the routine integration of these technologies in‐
to the assessment of this cohort of patients can be recommended.
4. Surgical management of the chemotherapy injured liver
When either clinical suspicion or pre-operative imaging suggest the presence of a chemo‐
therapy induced injury to the liver it may no longer be possible to resect all metastatic dis‐
ease whilst maintaining an adequate FLR to avoid the risk of liver failure. In this situation
two key surgical strategies have been described to reduce the risk of surgery i.e. pre-opera‐
tive portal vein embolisation and two-stage hepatectomy and these are discussed in more
detail below.
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4.1. Pre-operative portal vein embolisation
Portal vein embolisation (PVE) is a particularly useful technique in patients who have dis‐
ease which is technically resectable in a single operation but where so doing would lead to a
compromised FLR. As early as 1920 Rous and Larimore observed that if they ligated a single
branch of the portal vein in a rabbit there was atrophy of the ipsilateral lobe and hypertro‐
phy of the contralateral lobe.[80] As a clinical technique PVE was initially described by Ki‐
noshita et al. in 1986 as a means of limiting the extension of tumour thrombus in patients
with hepatocellular carcinoma.[81] Subsequently in 1990 Makuuchi et al. demonstrated the
safety and efficacy of this technique as a means of increasing the FLR in a series of 14 pa‐
tients undergoing resection of hilar cholangiocarcinoma.[82] In a prospective study Farges et
al. performed CT volumetry on patients undergoing pre-operative PVE and demonstrated
that in those patients with no underlying parenchymal disease the typical increase in FLR
was 16% whereas in those with chronic liver disease the typical increase in FLR was 9%.[83]
In 2010 Wicherts et al. reported a retrospective series of 67 patients who underwent liver re‐
section for colorectal metastases after pre-operative PVE with a cohort of 297 patients who
did not receive PVE. The authors observed that those patients treated with pre-operative
PVE demonstrated a significantly higher complication rate (55.5% vs. 41.1%; p = 0.035) al‐
though there was no difference in surgical mortality between groups. Whilst this difference
in morbidity is striking it is difficult to interpret since whilst all patients in the study under‐
went a major hepatectomy (≥3 Couinaud segments) 54% of those in the PVE group under‐
went a right trisectionectomy as compared to only 28% in the control group. What was
striking in this study however was that 32 of the patients treated with PVE did not proceed
to surgery and amongst these patients there were no 3 year survivors as compared to a 3
year survival rate of 44% in those who did undergo surgery.[84]
A similarly designed study by Pamecha et al. compared the outcome of 36 patients treated
with pre-operative PVE with 65 patients who did not receive PVE all of whom had a diagno‐
sis of colorectal metastases. Of the 36 patients treated with PVE 12 did not progress to sur‐
gery and had a median survival of 14 months as compared to 42 months in those who did
progress to surgery (p<0.0001). Again there was a tendency to higher morbidity in the PVE
group (36% vs. 20%) but in a similar manner to the study of Wicherts et al. more of these
patients had undergone a right trisectionectomy (22% vs. 11%).[85]
The most important finding in both of these series is that nearly a third of all patients select‐
ed to undergo pre-operative portal vein embolisation do not undergo subsequent surgery
and this is primarily a consequence of disease progression.[84, 85] It is likely that the most
important factor driving this disease progression is the compensatory increase in arterial
blood flow which occurs in the embolised lobe.[86] The blood supply of colorectal metasta‐
ses is predominantly derived from the hepatic artery[87] and it is probable that the increase
in arterial flow results in increased oxygen and nutrient supply to the tumour. In addition
following PVE there is an increase in the hepatic production of a wide variety of cytokines,
growth factors and other humoral factors that mediate liver regeneration and it may be that
these also contribute to the progression of metastatic disease.[88, 89]
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In summary PVE is a potentially useful technique for increasing the FLR in patients in
whom this is likely to be compromised there is a significant risk that the procedure will re‐
sult in disease progression rendering the patient inoperable and therefore must not be em‐
barked upon lightly.
4.2. Two-stage hepatectomy
For a proportion of patients presenting with bilobar disease it is not possible to clear the en‐
tire tumour burden by an extended resection alone (e.g. right trisectionectomy) but rather it
is necessary to combine an anatomical resection (e.g. or the right lobe) with multiple meta‐
stectomies from the contralateral lobe potentially resulting in an insufficient FLR, particular‐
ly in patients with a background liver injury (Figure 2). In such circumstances a PVE alone
would not be appropriate because of the significant risk of tumour progression in the FLR
and therefore a two stage resection should be considered. In the scenario described above
this would typically consist of an initial operation to clear the left liver of tumour using mul‐
tiple metastectomies followed several weeks later by a right hepatectomy. If it was felt at the
time of the primary operation that the hypertrophy induced by surgery alone would not
leave an adequate FLR for the second operation then it may be desirable to perform either
intra-operative ligation of the right portal vein or post-operative percutaneous portal vein
embolisation.[90] In this situation it is the authors preference to perform the latter procedure
thereby avoiding unnecessary dissection of the hilum prior to right hepatectomy.
Wicherts et al. reported the outcomes of 59 patients considered to be inoperable using a sin‐
gle stage procedure who were selected for a two stage approach. All of these patients under‐
went a primary surgical procedure which in the majority of cases consisted of a minor
hepatectomy (<3 Couinaud segments resected) the aim of which was to clear the left liver of
tumour. Subsequently 42 patients underwent a second procedure which was typically a ma‐
jor hepatic resection (≥3 Couinaud segments) and typically this took place 3 months after the
initial surgical procedure. It is of note that 17 patients selected for this approach did not un‐
dergo a second procedure primarily as a consequence of disease progression. The overall 5
year survival in this series was 31% when analysed on an intention to treat basis and this
did not differ, in a statistically significantly manner, from patients undergoing a single stage
hepatectomy over the same period in the authors unit.[91]
More recently Narita et al. reported the outcome of 79 patients treated using a two stage ap‐
proach. After the initial surgical procedure 75 of these patients were considered appropriate
to proceed to the second operation although the majority (92%) were thought to require por‐
tal vein embolisation to facilitate this. Of that cohort of patients 61 (78% of the original co‐
hort) eventually underwent a successful second operation. The main reasons for patients not
proceeding to a second procedure were tumour progression in 10 cases and insufficient re‐
generation of the FLR in a further 5 cases. It is of note that almost 1:6 of the patients who
underwent a second surgical procedure were found to have new disease in the previously
cleared FLR although this was dealt with at the time of surgery in all cases. In those patients
who underwent a successful two stage resection the overall 5 year survival was 32%. Of the
61 patients who were treated successfully by a two stage approach 11 went on to have a sub‐
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sequent resection of lung metastases although this had no effect on overall survival when
compared to the 50 patients who did not.[92]
Figure 2. Typical MRI scan of patient with bilobar disease who would be considered suitable for a two staged ap‐
proach to liver resection. With this distribution of disease a one stage approach would not leave an adequate FLR.
In a similar manner to PVE alone a two stage hepatectomy is a major undertaking and be‐
fore embarking on this both surgeon and patient should be aware that there is a significant
risk of not being able to complete the planned course of treatment. Despite this it does pro‐
vide an opportunity to achieve a meaningful long term survival in selected patients with ad‐
vanced disease.
5. The long term consequences of chemotherapy associated liver injury
Whilst the primary focus of this chapter is on the effects of chemotherapy associated liver
injury on the surgical management of patients with colorectal liver metastases it would not
be complete without some mention of the emerging evidence that this injury may have an
effect on long term disease specific outcomes. Tamandl et al. have suggested that the pres‐
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ence of the histological features of SOS within the resected liver of patients with colorectal
liver metastases may have a negative impact on long term disease specific survival. In par‐
ticular patients with SOS demonstrated a significantly poorer 3 year progression free surviv‐
al (6.7% vs. 22.7%; p=0.006) a finding which was upheld on multivariate analysis (Hazard
Ratio 2.20; p=0.006). Specifically patients with SOS demonstrated a higher rate of intra-hep‐
atic recurrence following surgery (66.7% vs. 30.5%; p=0.003) and not surprisingly this was
associated with an increased risk of early all cause mortality on multivariate analysis (Haz‐
ard Ratio 2.90; p<0.001).[61]
A major criticism of the study of Tamandl et al. is that it includes only small numbers of pa‐
tients (n=20 with SOS) and therefore it is difficult to draw definitive conclusions.[61] None
the less a recent paper by Vreuls et al. has reported that the development of SOS may be
associated with a poorer tumour response to Oxaliplatin based chemotherapy which the au‐
thors propose may be a consequence of tissue hypoperfusion leading to diminished leading
to impaired delivery of chemotherapy to the tumour.[93] An alternative explanation may be
that SOS is associated with increased expression of the chemokine CCL20 within the liver
which is known to act as a chemo-attractant for colorectal cancer cells.[94] At the same time
as this is occurring within the liver Oxaliplatin chemotherapy also results in increased ex‐
pression of the CCL20 receptor CCR6 within colorectal liver metastases thereby increasing
the migration and proliferation of tumour cells in response to CCL20.[95, 96] It may there‐
fore be that the presence of SOS leads to the establishment of an autocrine signalling loop
which favours the further growth and development of colorectal liver metastases.[97]
This emerging evidence is clearly a cause for concern and, if proven to be true, would add
further impetus to the drive to develop strategies for the prevention of liver injury in pa‐
tients being treated with systemic chemotherapy.
6. Conclusion
Advances in chemotherapy over the last decade or so have revolutionised the care for pa‐
tients with colorectal liver metastases with the end result that patients who historically
would have been considered inoperable are now able to undergo potentially curative surgi‐
cal resection. The pay off for this advance has been the development of a chemotherapy as‐
sociated injury to the liver the nature of which is determined the specific regimens used.
There is no specific test that is able to reliably detect the presence of an injured liver paren‐
chyma and ultimately surgeons must maintain a high index of suspicion for its presence
particularly in patients who have received multiple cycles of chemotherapy over a pro‐
longed period of time. When a liver injury is present it is important that the surgical ap‐
proach is considered carefully and makes allowances for the possibility of an impaired FLR
with a subsequent risk of post operative liver failure. In those situations where there is a
high risk of an insufficient FLR it may be appropriate to utilise techniques such as PVE or
two stage hepatectomy although there is a risk with both these techniques of treatment fail‐
ure as a consequence of disease progression.
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